Silexion Therapeutics Ltd.(SLXN)Earnings, Financials & Key RatiosSilexion Therapeutics Ltd. (SLXN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious liquidity position, highlighted by a cash balance of only $2.4 million against quarterly losses of $2.7 million, suggests an imminent risk of significant shareholder dilution.
Silexion Therapeutics Ltd. (SLXN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Silexion Therapeutics Ltd. (SLXN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.85vs $1.29+34.1% | — |
| Q2 2026 | Mar 17, 2026 | $2.38vs $1.17-103.8% | — |
| Q4 2025 | Nov 12, 2025 | $2.88vs $3.40+15.3% | — |
| Q3 2025 | Aug 12, 2025 | $4.32vs $3.15-37.1% | — |
Recent stock market news and headlines for Silexion Therapeutics Ltd. (SLXN)
CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany
Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company's Chief Executive Officer, Ilan Hadar, and the Company's Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.
Key metrics vs top competitors for Silexion Therapeutics Ltd. (SLXN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.85 | $920.65K | -0.03 | — | — | -457.63% | — | |
| $19.18 | $2.02B | -2.69 | 15.58% | 2.98% | 4.89% | — | |
| $86.55 | $12.19B | -7094.26 | 23258.15% | -48.38% | -55.09% | — | |
| $17.84 | $2B | -4.68 | 16.92% | -597.04% | -57.27% | — | |
| $83.18 | $13.75B | -34.95 | 33.87% | -30.87% | -58.57% | — | |
| $649.81 | $67.52B | 15.67 | 0.99% | 29.65% | 14.32% | — |
Silexion Therapeutics Ltd. (SLXN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Silexion Therapeutics Ltd. (SLXN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 18, 2026·SEC
May 15, 2026·SEC
May 14, 2026·SEC
Get notified when SLXN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Silexion Therapeutics Ltd. (SLXN) stock FAQ — growth, dividends, profitability & financials explained
Silexion Therapeutics Ltd. (SLXN) reported a net loss of $12.9M for fiscal year 2025.
Silexion Therapeutics Ltd. (SLXN) has a return on equity (ROE) of -457.6%. Negative ROE indicates the company is unprofitable.
Silexion Therapeutics Ltd. (SLXN) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.
